|
1
|
Folkman J: Angiogenesis in cancer,
vascular, rheumatoid and other disease. Nat Med. 1:27–31. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Carmeliet P and Jain RK: Angiogenesis in
cancer and other diseases. Nature. 407:249–257. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
de Araujo-Filho VJ, Alves VA, de Castro
IV, Lourenço SV, Cernea CR, Brandão LG and Ferraz AR: Vascular
endothelial growth factor expression in invasive papillary thyroid
carcinoma. Thyroid. 19:1233–1237. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Weidner N, Carroll PR, Flax J, Blumenfeld
W and Folkman J: Tumor angiogenesis correlates with metastasis in
invasive prostate carcinoma. Am J Pathol. 143:401–409.
1993.PubMed/NCBI
|
|
5
|
Hurwitz H, Fehrenbacher L, Novotny W,
Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S,
Holmgren E, et al: Bevacizumab plus irinotecan, fluorouracil, and
leucovorin for metastatic colorectal cancer. N Engl J Med.
350:2335–2342. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Gruber JJ and Colevas AD: Differentiated
thyroid cancer: Focus on emerging treatments for radioactive
iodine-refractory patients. Oncologist. 20:113–126. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Gotink KJ and Verheul HM: Anti-angiogenic
tyrosine kinase inhibitors: What is their mechanism of action?
Angiogenesis. 13:1–14. 2010. View Article : Google Scholar :
|
|
8
|
Blankenberg FG, Levashova Z, Sarkar SK,
Pizzonia J, Backer MV and Backer JM: Noninvasive assessment of
tumor VEGF receptors in response to treatment with pazopanib: A
molecular imaging study. Transl Oncol. 3:56–64. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Toi M, Inada K, Suzuki H and Tominaga T:
Tumor angiogenesis in breast cancer: Its importance as a prognostic
indicator and the association with vascular endothelial growth
factor expression. Breast Cancer Res Treat. 36:193–204. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Folkman J: Angiogenesis: An organizing
principle for drug discovery? Nat Rev Drug Discov. 6:273–286. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Iagaru A, Chen X and Gambhir SS: Molecular
imaging can accelerate anti-angiogenic drug development and
testing. Nat Clin Pract Oncol. 4:556–557. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Taurone S, Galli F, Signore A, Agostinelli
E, Dierckx RA, Minni A, Pucci M and Artico M: VEGF in nuclear
medicine: Clinical application in cancer and future perspectives
(Review). Int J Oncol. 49:437–447. 2016.PubMed/NCBI
|
|
13
|
Goel HL and Mercurio AM: VEGF targets the
tumour cell. Nat Rev Cancer. 13:871–882. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Dijkgraaf I and Boerman OC: Molecular
imaging of angiogenesis with SPECT. Eur J Nucl Med Mol Imaging.
37(Suppl 1): S104–S113. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cai W and Chen X: Multimodality molecular
imaging of tumor angiogenesis. J Nucl Med. 49(Suppl 2): 113–128.
2008. View Article : Google Scholar
|
|
16
|
Laemmli UK: Cleavage of structural
proteins during the assembly of the head of bacteriophage T4.
Nature. 227:680–685. 1970. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zenner HL, Collinson LM, Michaux G and
Cutler DF: High-pressure freezing provides insights into
Weibel-Palade body biogenesis. J Cell Sci. 120:2117–2125. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ke CC, Liu RS, Yang AH, Liu CS, Chi CW,
Tseng LM, Tsai YF, Ho JH, Lee CH and Lee OK: CD133-expressing
thyroid cancer cells are undifferentiated, radioresistant and
survive radioiodide therapy. Eur J Nucl Med Mol Imaging. 40:61–71.
2013. View Article : Google Scholar
|
|
19
|
Paudyal B, Paudyal P, Shah D, Tominaga H,
Tsushima Y and Endo K: Detection of vascular endothelial growth
factor in colon cancer xenografts using bevacizumab based near
infrared fluorophore conjugate. J Biomed Sci. 21:352014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Challeton C, Branea F, Schlumberger M,
Gaillard N, de Vathaire F, Badie C, Antonini P and Parmentier C:
Characterization and radiosensitivity at high or low dose rate of
four cell lines derived from human thyroid tumors. Int J Radiat
Oncol Biol Phys. 37:163–169. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Björke H and Andersson K: Automated,
high-resolution cellular retention and uptake studies in vitro.
Appl Radiat Isot. 64:901–905. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Soluri A, Massari R, Trotta C, Montani L,
Iurlaro G, Mangano AM, Scopinaro F and Scafè R: New imaging probe
with crystals integrated in the collimator's square holes. Nucl
Instrum Methods Phys Res A. 554:331–339. 2005. View Article : Google Scholar
|
|
23
|
Galli F, Iodice V, Lauri C and Signore A:
New approaches to image thyroid cancer cells and microenvironment.
Q J Nucl Med Mol Imaging. 59:184–196. 2015.PubMed/NCBI
|
|
24
|
Stacy MR, Maxfield MW and Sinusas AJ:
Targeted molecular imaging of angiogenesis in PET and SPECT: A
review. Yale J Biol Med. 85:75–86. 2012.PubMed/NCBI
|
|
25
|
Schneider TC, Abdulrahman RM, Corssmit EP,
Morreau H, Smit JW and Kapiteijn E: Long-term analysis of the
efficacy and tolerability of sorafenib in advanced radio-iodine
refractory differentiated thyroid carcinoma: Final results of a
phase II trial. Eur J Endocrinol. 167:643–650. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Stollman TH, Scheer MG, Franssen GM,
Verrijp KN, Oyen WJ, Ruers TJ, Leenders WP and Boerman OC: Tumor
accumulation of radiolabeled bevacizumab due to targeting of cell-
and matrix-associated VEGF-A isoforms. Cancer Biother Radiopharm.
24:195–200. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Van Dongen GA, Huisman MC, Boellaard R,
Harry Hendrikse N, Windhorst AD, Visser GW, Molthoff CF and Vugts
DJ: 89Zr-immuno-PET for imaging of long circulating drugs and
disease targets: Why, how and when to be applied? Q J Nucl Med Mol
Imaging. 59:18–38. 2015.
|
|
28
|
Blankenberg FG, Backer MV, Levashova Z,
Patel V and Backer JM: In vivo tumor angiogenesis imaging with
site-specific labeled (99m)Tc-HYNIC-VEGF. Eur J Nucl Med Mol
Imaging. 33:841–848. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Meyer JP, Edwards KJ, Kozlowski P, Backer
MV, Backer JM and Lewis JS: Selective imaging of VEGFR-1 and
VEGFR-2 receptors using 89Zr-labeled single-chain VEGF mutants. J
Nucl Med. 57:1811–1816. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Backer MV, Levashova Z, Patel V, Jehning
BT, Claffey K, Blankenberg FG and Backer JM: Molecular imaging of
VEGF receptors in angiogenic vasculature with single-chain
VEGF-based probes. Nat Med. 13:504–509. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Chen K, Cai W, Li ZB, Wang H and Chen X:
Quantitative PET imaging of VEGF receptor expression. Mol Imaging
Biol. 11:15–22. 2009. View Article : Google Scholar
|
|
32
|
Signore A, Chianelli M, Annovazzi A,
Bonanno E, Spagnoli LG, Pozzilli P, Pallone F and Biancone L:
123I-interleukin-2 scin-tigraphy for in vivo assessment
of intestinal mononuclear cell infiltration in Crohn's disease. J
Nucl Med. 41:242–249. 2000.PubMed/NCBI
|
|
33
|
Signore A, Capriotti G, Chianelli M,
Bonanno E, Galli F, Catalano C, Quintero AM, De Toma G, Manfrini S
and Pozzilli P; Action LADA Group: Detection of insulitis by
pancreatic scin-tigraphy with 99mTc-labeled IL-2 and MRI
in patients with LADA (Action LADA 10). Diabetes Care. 38:652–658.
2015.PubMed/NCBI
|
|
34
|
Kang CM, Koo HJ, Choe YS, Choi JY, Lee KH
and Kim BT: 68Ga-NODAGA-VEGF121 for in vivo
imaging of VEGF receptor expression. Nucl Med Biol. 41:51–57. 2014.
View Article : Google Scholar
|
|
35
|
Gaykema SB, Brouwers AH, Lub-de Hooge MN,
Pleijhuis RG, Timmer-Bosscha H, Pot L, van Dam GM, van der Meulen
SB, de Jong JR, Bart J, et al: 89Zr-bevacizumab PET imaging in
primary breast cancer. J Nucl Med. 54:1014–1018. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Cai C, Böttcher MC, Werner JA and Mandic
R: Differential expression of VEGF121, VEGF165 and VEGF189 in
angiomas and squamous cell carcinoma cell lines of the head and
neck. Anticancer Res. 30:805–810. 2010.PubMed/NCBI
|
|
37
|
Galli F, Manni I, Piaggio G, Balogh L,
Weintraub BD, Szkudlinski MW, Fremont V, Dierckx RA and Signore A:
(99m)Tc-labeled-rhTSH analogue (TR1401) for imaging poorly
differentiated metastatic thyroid cancer. Thyroid. 24:1297–1308.
2014. View Article : Google Scholar : PubMed/NCBI
|
